10 Stocks Shaking the Market

Some stocks are one-hit wonders, making a big splash when they first appear, then quickly fizzling into obscurity or oblivion. But for other stocks, that initial big move is only a preview of bigger and better gains to come.

Today, we've compiled 10 stocks that made some of the biggest upward moves over the past month. We then paired the stocks with the ratings issued by our Motley Fool CAPS community. The more stars a stock has (out of five), the greater CAPS members' faith in that company's ability to keep on beating the market.

Stock

30-Day Change

CAPS Rating

CEL-SCI (NYSE: CVM  )

331.09%

**

Newcastle Investment

117.57%

**

Helicos BioSciences

92.48%

**

Keryx Biopharmaceuticals (Nasdaq: KERX  )

78.20%

**

AMR (NYSE: AMR  )

73.99%

*

US Airways (NYSE: LCC  )

72.38%

*

Sinovac Biotech

70.59%

**

VIVUS (Nasdaq: VVUS  )

69.32%

**

Strategic Hotels & Resorts (NYSE: BEE  )

68.85%

***

KV Pharmaceutical (NYSE: KV-A  )

62.87%

*****

Thirty-day change from Aug. 10 to Sept. 9.

As the markets whipsaw to changes in consumer sentiment, there will be weeks like this one, where we see gains that are exceptionally ahead of the pace of the movers and shakers of prior weeks. So before we get shaken out again, let's see why the CAPS community thinks one of these companies might continue to outperform the market.

A mighty temblor
We haven't heard as much about swine flu outbreaks recently, but we're heading into cold and flu season and health officials worldwide are anticipating new and far more extensive cases to be reported. As if on the verge of hysteria, China says its cases of H1N1 virus may rise from the 3,500 cases that have been reported over the last two weeks or so to the tens of millions.

But that seems almost tame compared to reports that the U.S. has some 159 million high-risk people who will not be vaccinated in time to protect them from the outbreak.

There is a race on amongst pharmaceuticals and biotechs to develop vaccines to help prevent the virus from spreading, but CEL-SCI really shook things up because it appears to have a treatment for those already seriously ill. Although we might hope against a worsening pandemic, if the most alarmist predictions are true -- that there simply won't be enough vaccines available to protect people -- then CEL-SCI may be positioned to capitalize on the need for its therapy to treat the hordes once they've contracted the disease.

CAPS member MichaelinWA thinks the biotech has reached an inflection point, though he's well aware that momentum can change at a moment's notice if things don't go as planned:

Cel-Sci is at potential major turning point. The Government is interested in their LEAPS technology for an H1N1 treatment/prevention that offers potential effectiveness even in the event of a mutating virus. Because of the promise that LEAPS offers, the FDA is working with Cel-Sci to expedite clinical trials of LEAPS-H1N1. Of course, clinicals can fail, but when they are successful, they can change the prospects for small cap biotechnology companies in a major way. If LEAPS-H1N1 offers promise, there could be an immediate worldwide market for it.

Or not. Despite the hoopla carrying this company from literally pennies a share to around $2, the biotech is only entering phase 1 clinical trials of its novel LEAPS technology. While it may have potential down the road for combating viruses, that is still a long, long way off. Anyone investing in CEL-SCI today because of its potential for treating swine flu will surely be disappointed when they realize that the company is running far behind the pack.

CEL-SCI is late to the game, as until only recently it was developing a treatment for head and neck cancer. Its Multikine therapy may enter phase 3 trials, but only if it can get the funding -- it got FDA approval back in January 2007 to perform those trials -- and only recently started churning out press releases attaching itself to the swine flu virus. Further, a recent SEC filing shows its new Multikine manufacturing facility will be more useful as a contract facility for others long before it produces anything for itself.

In short, the company has little in the way of concrete developments to offer investors, but its officers and directors hold millions of stock options at just pennies on the dollar -- the CEO was issued 4 million options just this past July, when the new developments started rolling out -- and they'll be allowed to exercise one-third of them upon enrolling 400 patients in the Multikine phase 3 trials.

While CEL-SCI caused a few tremors with all the swine flu talk, I'd be surprised if it doesn't eventually succumb to the hype malaise.

Shake, rattle, and roll
It pays to start your own research on these stocks on Motley Fool CAPS. Read a company's financial reports, scrutinize key data and charts, and examine the comments your fellow investors have made -- all from a stock's CAPS page.

Try any of our Foolish newsletter services today, free for 30 days.

Fool contributor Rich Duprey does not have a financial position in any of the stocks mentioned in this article. You can see his holdings here. You can shake, rattle, and roll The Motley Fool's disclosure policy, but it still won't break.


Read/Post Comments (15) | Recommend This Article (24)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On September 22, 2009, at 3:49 PM, johnnettles wrote:

    There is a race on amongst pharmaceuticals and biotechs to develop vaccines to help prevent the virus from spreading, but CEL-SCI really shook things up because it appears to have a treatment for those already seriously ill.

    These are for critically ill and have been working with the government. It would be an iv form. There are h1n1 and h5n1 co-infections that have been detected coming from individuals out of Saudi Arabia into egypt and this infection is spreading. In 2003 bush started operation bio shield with many companies for cases like this, Example Hgsi, produces abthrax to thwart anthrax attacks.. Its not a one hit wonder unless the press just kills it

  • Report this Comment On September 22, 2009, at 3:59 PM, poconobear wrote:

    NO hype here, as u mentioned in the article, just the fact that other compamies will be using the facility makes it a big plus. its the only facility like it un the USA. its the ability to control studies at low temperatures that makes the facility what it is. the stock is a no brainer. i bought in at .50. bought more when they offered shares at 1.40, and still buying!

  • Report this Comment On September 22, 2009, at 4:17 PM, marylkick wrote:

    It seems that every stock I buy gets shot down by you or Cramer. It will be going up nicely and then you slam the door.

  • Report this Comment On September 22, 2009, at 4:18 PM, johnnettles wrote:

    CEL-SCI (NYSE: CVM)

    can anyone find another cold filled lab as this one in the United States for processing such... geesh

  • Report this Comment On September 22, 2009, at 4:18 PM, beawinner2 wrote:

    HAHAHAHA This article was written MIONTHS AGO and hasn't been updated on the FUNDING situation.

    They have the money they need for LEAPS AND Multikine, and more.

    What another "FOOLS" joke of an article.

    What a lousy, aweful attempt at bashing to get into CVM cheap. Jerk.

  • Report this Comment On September 22, 2009, at 4:20 PM, beawinner2 wrote:

    "FOOLS" you need to re-think your business or quit.

    What a disappointment this subscription is.

  • Report this Comment On September 22, 2009, at 4:36 PM, PiedmontMan wrote:

    Hey Rich,

    You missed CHIP.

    Your late and all wrong on CVM.

    Do your research.

    You better start looking for another job, because your writing sucks. Party too hard this weekend and fall behind.

    PAY ATTENTION TO WHAT"S GOING ON DUDE!

  • Report this Comment On September 22, 2009, at 4:41 PM, RainierMan wrote:

    Running way back in the pack, eh?

    And just how far along to you think NVAX and VICL are in testing their vaccines? They're not trading at $1.80 per share.

    You don't need years of clinicals for vaccines, you need months. And in any case, IF the LEAPS technology is successful, it's not your garden variety vaccine.

    As for funding, they are now flush with cash. The manufacturing plant could end up being a revenue stream.

  • Report this Comment On September 22, 2009, at 5:05 PM, bobbleheads wrote:

    As far as your late to the game comment, please reference the CDC site for the "emergency use authorization". This is how CVM can "catch" up.

    http://www.cdc.gov/h1n1flu/eua/qa.htm

    If positive results are shown for a treatment, expedited approval can be given within weeks, not months/years.

  • Report this Comment On September 22, 2009, at 5:18 PM, johnnettles wrote:

    hello,,,, one more time cvm is not a vaccine people ,,, gsk and sanfi and a few others have the vaccine,,,

    Cvm is for treating people infected with h1n1 and probably h4n1 before its over... when your in the hospital is when cvm comes into play, not a shot in the arm at walgreens

  • Report this Comment On September 22, 2009, at 5:18 PM, johnnettles wrote:

    h5n` wxcuse me

  • Report this Comment On September 22, 2009, at 5:46 PM, pigeondic wrote:

    The post above pretty much said what I was thinking, Iwould like to add I 've been reading your trash for years and am amazed you idiots are still in business. At least print the facts and make sure they are up to date you boobs. Pigeondic

  • Report this Comment On September 23, 2009, at 1:43 AM, justasclueless wrote:

    Just another poorly researched, self-serving article from the Fool, devoid of facts.

  • Report this Comment On September 23, 2009, at 6:28 PM, Fool wrote:

    kerx could go all the way

  • Report this Comment On September 26, 2009, at 2:14 PM, Fool wrote:

    how many biotechs have remained in business

    since 1983 following the same course. cvm is way

    over due to become one of the next generation of

    major health care players. they finally got the boost

    they needed from h1n1, but the process applies to so many more situations. please do your homework.

Add your comment.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 990049, ~/Articles/ArticleHandler.aspx, 9/1/2014 11:04:13 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement